Search
Elinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Categories: Heterocyclic Compounds, 2-RingXaliproden
go.drugbank.com/drugs/DB06393InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Serotonin 5-HT1 Receptor AntagonistsBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalBazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.
Categories: Heterocyclic Compounds, 2-RingTelavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalEtraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. … Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: INTELENCE®TABLETAS 200MGCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalAn advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset
Categories: Heterocyclic Compounds, 2-RingSynonyms: [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acidAplaviroc
go.drugbank.com/drugs/DB06497InvestigationalA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
Categories: Heterocyclic Compounds, 1-RingResiquimod
go.drugbank.com/drugs/DB06530InvestigationalIt is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.
Categories: Heterocyclic Compounds, 1-RingPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].